Ignite Creation Date:
2025-12-25 @ 1:03 AM
Ignite Modification Date:
2025-12-30 @ 12:03 PM
Study NCT ID:
NCT02049593
Status:
COMPLETED
Last Update Posted:
2022-09-26
First Post:
2014-01-27
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Sponsor:
Jonsson Comprehensive Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-06-12
Start Date Type:
ACTUAL
Primary Completion Date:
2019-10-07
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-10-07
Completion Date Type:
ACTUAL
First Submit Date:
2014-01-27
First Submit QC Date:
None
Study First Post Date:
2014-01-30
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-09-22
Last Update Post Date:
2022-09-26
Last Update Post Date Type:
ACTUAL